Navidea Biopharmaceuticals, Inc. (NAVB): Price and Financial Metrics


Navidea Biopharmaceuticals, Inc. (NAVB)

Today's Latest Price: $2.42 USD

0.07 (-2.81%)

Updated Oct 29 8:00pm

Add NAVB to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 364 in Miscellaneous

See all "A" rated Strong Buy stocks

NAVB Stock Summary

  • NAVB's price/sales ratio is 82.14; that's higher than the P/S ratio of 96.85% of US stocks.
  • NAVB's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 3.97% of US stocks.
  • The volatility of Navidea Biopharmaceuticals Inc's share price is greater than that of 95.35% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Navidea Biopharmaceuticals Inc are OIIM, AKER, AWRE, UTSI, and KMDA.
  • Visit NAVB's SEC page to see the company's official filings. To visit the company's web site, go to www.navidea.com.

NAVB Stock Price Chart Interactive Chart >

Price chart for NAVB

NAVB Price/Volume Stats

Current price $2.42 52-week high $5.36
Prev. close $2.49 52-week low $0.63
Day low $2.40 Volume 67,054
Day high $2.54 Avg. volume 691,289
50-day MA $2.79 Dividend yield N/A
200-day MA $2.30 Market Cap 63.69M

NAVB Latest News Stream


Event/Time News Detail
Loading, please wait...

NAVB Latest Social Stream


Loading social stream, please wait...

View Full NAVB Social Stream

Latest NAVB News From Around the Web

Below are the latest news stories about Navidea Biopharmaceuticals Inc that investors may wish to consider to help them evaluate NAVB as an investment opportunity.

Navidea Biopharmaceuticals: Too Many Risks Involved

Introduction Navidea's (NAVB) past has been very shaky. In 2014, the company's first approved product Lymphoseek for solid tumors initially created a big hype. However, due to debt issues with creditors, the company somehow never managed to return any significant value for shareholders. For me, the topic was too complex...

Tien Duy Vo on Seeking Alpha | September 14, 2020

Navidea Biopharmaceuticals Wins Dismissal of Platinum Loan Litigation

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that on September 2, 2020 the Supreme Court of the State of New York, New York County (the “Court”) has dismissed with prejudice Platinum-Montaur Life Sciences LLC’s (“Platinum-Montaur”) law suit against the Company. In the case, Platinum-Montaur asserted severa

Business Wire | September 2, 2020

Navidea Biopharmaceuticals, Inc. (NAVB) CEO Jed Latkin on Q2 2020 Results - Earnings Call Transcript

Navidea Biopharmaceuticals, Inc. (NAVB) Q2 2020 Results Earnings Conference Call August 13, 2020, 5:00 pm ET Company Participants Jed Latkin - Chief Executive Officer, Chief Financial Officer and Chief Operating Officer Mike Rosol - Chief Medical Officer Erika Gibson - Director of Finance and Administration Conference Call Participants Michael Okunewitch...

SA Transcripts on Seeking Alpha | August 15, 2020

Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the second quarter and year-to-date for the period ended June 30, 2020. “The past four months have been truly momentous for the company. The successful second interim look showed how valuable our diagnostic agent will be for the effective manag

Business Wire | August 13, 2020

Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma

DUBLIN, Ohio--(BUSINESS WIRE)--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that it has signed a binding memorandum of understanding (“MOU”) with Jubilant Draximage Inc. dba Jubilant Radiopharma, Radiopharmaceuticals Division (“Jubilant”). The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement (“ELD

Business Wire | August 10, 2020

Read More 'NAVB' Stories Here

NAVB Price Returns

1-mo -10.37%
3-mo -49.37%
6-mo 185.41%
1-year 160.22%
3-year -71.19%
5-year -94.01%
YTD 92.06%
2019 -37.00%
2018 -72.22%
2017 -43.75%
2016 -51.88%
2015 -29.63%

Continue Researching NAVB

Here are a few links from around the web to help you further your research on Navidea Biopharmaceuticals Inc's stock as an investment opportunity:

Navidea Biopharmaceuticals Inc (NAVB) Stock Price | Nasdaq
Navidea Biopharmaceuticals Inc (NAVB) Stock Quote, History and News - Yahoo Finance
Navidea Biopharmaceuticals Inc (NAVB) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7828 seconds.